Brief: Vbl Therapeutics Resumes U.S. Enrollment In Oval Phase 3 Trial As FDA Authorizes Clinical Use Of Vb-111 Batches Produced In Modiin Facility

Notable Labs

30/08/2021 12:36

Aug 30 (Reuters) - Vascular Biogenics Ltd  VBLT.O :
    * VBL THERAPEUTICS RESUMES U.S. ENROLLMENT IN OVAL PHASE 3
TRIAL
AS FDA AUTHORIZES CLINICAL USE OF VB-111 BATCHES PRODUCED IN
MODIIN FACILITY
    * VASCULAR BIOGENICS - U.S. FDA CMC CLEARANCE OF VB-111
PRODUCED
IN MODIIN, ISRAEL FACILITY AN IMPORTANT MILESTONE TOWARD
POTENTIAL COMMERCIALIZATION
    * VASCULAR BIOGENICS LTD - OVAL PHASE 3 TRIAL EVALUATING
VB-111 IN
PLATINUM RESISTANT OVARIAN CANCER HAS RECRUITED NEARLY 80% OF
TARGET ENROLLMENT
    * VASCULAR BIOGENICS LTD - OVAL PHASE 3 TRIAL REMAINS ON
TRACK TO
COMPLETE ENROLLMENT IN 1Q22
    * VASCULAR BIOGENICS LTD - OVAL PFS READOUT EXPECTED IN 2H22
MAY
SUPPORT BLA SUBMISSION

Source text for Eikon:  ID:nGNXM8Ghb 
Further company coverage:  VBLT.O 

 ((Reuters.Briefs@thomsonreuters.com;))